The Star Health and Allied Insurance Company Limited board meeting held on October 28, 2025, approved the unaudited standalone financial results for Q2 and half year ended September 30, 2025. The company reported growth in revenue and profit compared to the previous quarter and the corresponding quarter last year. The board meeting also acknowledged a Limited Audit Review Report by its joint auditors. The meeting duration was from 12:00 Noon to 5:55 PM IST.​

In detail, the company’s Q2 revenue stood at Rs. 8372.98 crores, up from Rs. 794710 lakhs (Rs. 7947.10 crores) in Q1 2025, representing a 5.25% increase quarter-on-quarter (QoQ). Year-on-year (YoY), revenue grew from Rs. 7113.53 crores in Q2 2024, marking a 17.63% increase. Profit after tax in Q2 was Rs. 317.42 crores versus Rs. 262.52 crores in Q1, an increase of 20.94% QoQ. Compared to Rs. 430.21 crores in Q2 2024, there was a decline of 26.16% YoY in profit. The company has applied a revised accounting policy for recognizing gross written premiums effective October 1, 2024, as per IRDAI regulations.​

Star Health and Allied Insurance Company Limited is a prominent health insurance provider in India, specializing in standalone health insurance products including individual and family health plans, critical illness insurance, and group insurance schemes. The company has faced recent challenges such as a cybersecurity incident in August 2024 and related regulatory scrutiny, including a Rs. 3.39 crore penalty paid in September 2025. It continues to be a market leader with expanding business volumes and customer reach, adapting to evolving regulatory standards.​

For the quarter ended September 30, 2025, Star Health exhibited a solid financial performance with steady revenue growth but some profit volatility, partly due to changes in premium recognition policies and seasonality effects in health insurance claims. The company reported revenues of Rs. 8372.98 crores and profit after tax of Rs. 317.42 crores for Q2. The Solvency ratio stood at 2.21, expenses of management to net written premium ratio around 31.59%, and net commission ratio approximately 14.43%. The company’s earnings per share (EPS) after extraordinary items was Rs. 0.92 diluted. There are no widely known famous individual investors specific to Star Health publicly acknowledged in 2025.​

The above table summarizes the financial performance comparison highlighting the increase in revenue and profit quarter-over-quarter, alongside a strong year-on-year revenue growth but a dip in profit compared to the prior year quarter.

This financial snapshot underscores Star Health’s ongoing resilience and growth as a major player in India’s health insurance market, navigating regulatory changes and market dynamics effectively.